HOME >> BIOLOGY >> NEWS
Other highlights in the July 7 JNCI

Study Evaluates Design of Phase I Trials for Targeted Cancer Drugs

One purpose of a phase I clinical trial of a new cytotoxic drug is to determine the side effects associated with increasing drug dose, i.e., determine the dose that produces the maximum effect at which the toxicity can still be tolerated. New targeted, non-cytotoxic anticancer agents, such as small-molecule kinase inhibitors, pose challenges to this paradigm because they can achieve their maximum effect at levels lower than the maximum tolerated dose.

In a new study, Wendy R. Parulekar, M.D., and Elizabeth A. Eisenhauer, M.D., of Queen's University in Kingston, Ontario, reviewed endpoints used in 60 published phase I studies of targeted, non-cytotoxic anticancer agents. They found that the majority of studies used the traditional endpoint of toxicity to determine the recommended dose for the phase II trials. Nontraditional endpoints, such as measures of molecular drug effects in tumor or surrogate tissue or functional imaging studies, were not routinely incorporated into the study design and rarely formed the primary basis for dose selection.

The authors conclude that although phase I studies of targeted anticancer agents in general continue to use traditional endpoints for selection of the recommended phase II dose, suitable molecular measures of drug effect and the means to incorporate them in the early drug development process are needed to optimize dose selection and drug development strategies.

In an editorial, Edward L. Korn, Ph.D., of the National Cancer Institute, discusses the assumptions and considerations required for choosing an endpoint in a phase I trial of a cytotoxic agent, and the challenges in using nontraditional endpoints for the dose selection of targeted, non-cytotoxic agents.

Contact: Wendy Parulekar, Queen's University, wparulekar@ctg.queensu.ca


Possible T
'"/>

Contact: Sarah L. Zielinski
jncimedia@oupjournals.org
301-841-1287
Journal of the National Cancer Institute
6-Jul-2004


Page: 1 2 3

Related biology news :

1. Other highlights in the September 1 JNCI
2. Other highlights in the August 18 JNCI
3. Other highlights in the August 4 JNCI
4. Other highlights in the June 16 JNCI
5. Other Highlights in the June 2 JNCI
6. Other highlights in the May 19 JNCI
7. Other highlights in the May 5 JNCI
8. Other highlights of the March 17 issue of JNCI
9. Other highlights in the March 3 issue of JNCI
10. Other highlights in the February 18 issue of JNCI
11. Other highlights in the February 4 issue of JNCI

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/18/2018)... ... December 18, 2018 , ... The ... intelligence into client marketing. The technology has been effective at reducing patient acquisition ... has been working with clients nationwide on patient acquisition marketing programs. Traditional marketing ...
(Date:12/13/2018)... ... ... Study Protocol Summary of QC Procedure , 1 – Patient Enrolment (with Ethical ... site., 3 - Three photos captured with Apple iPad and transferred to each Site's ... moved to eAdjudication® and submitted to Reviewers., 6 - Reviewers (blinded) repeats IGA ...
(Date:12/13/2018)... ... 2018 , ... New research by Florida Polytechnic University faculty and students has ... one of the main causes of car accidents and fatalities on the roads. ... assistant professor of computer science, uses a microcomputer, a camera, and a buzzer. The ...
Breaking Biology News(10 mins):
(Date:12/19/2018)... (PRWEB) , ... December 19, 2018 , ... ... procedures at its first rate Stem Cell Training Course in Las Vegas. Training ... women. As regenerative procedures explode in popularity nationwide for aesthetics, having the training ...
(Date:12/14/2018)... ... December 14, 2018 , ... NOVA OCULUS PARTNERS, LLC, and ... light to immediately begin a clinical patient trial in Edmonton using their pioneering ... Health Canada has granted what is called an Investigational Testing Authorization for the ...
(Date:12/10/2018)... (PRWEB) , ... December 10, ... ... fully integrated Contract Development and Manufacturing Organization (CDMO) with sites in China ... optimization, cGMP manufacturing, and aseptic fill finish solutions for monoclonal antibody (mAb) ...
(Date:11/29/2018)... ... November 29, 2018 , ... RAGS, today announced the ... Kickstart Seed Fund, with participation from existing investor and board member Jeremy Andrus, CEO ... of Cotopaxi. The additional funding will enable the company to accelerate its growth and ...
Breaking Biology Technology:
Cached News: